Journal Article

COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls

Englund, Simon, Nilsson, Petra, Frisell, Thomas, Fogdell‐Hahn, Anna, Langer‐Gould, Annette, Gunnarsson, Martin, Salzer, Jonatan, Svenningsson, Anders, Mellergård, Johan, Piehl, Fredrik, Burman, Joachim, Hillert, Jan, Longinetti, Elisa, Bower, Hannah, Lycke, Jan, Fink, Katharina, Olsson, Tomas, McKay, Kyla A

2022

Overview

Objective To estimate risks for all‐cause mortality and for severe COVID‐19 in multiple sclerosis patients and across relapsing–remitting multiple sclerosis patients exposed to disease‐modifying therapies. Methods We conducted a Swedish nationwide population‐based multi‐register linkage cohort study and followed all multiple sclerosis patients (n = 17,692 in March 2020), individually age‐, sex‐, and region‐matched to five population‐based controls (n = 86,176 in March 2020) during March 2020–June 2021. We compared annual all‐cause mortality within and across cohorts, and assessed incidence rates and relative risks for hospitalization, intensive care admission, and death due to COVID‐19 in relation to disease‐modifying therapy use, using Cox regression. Results Absolute all‐cause mortality among multiple sclerosis patients was higher from March to December 2020 than in previous years, but relative risks versus the population‐based controls were similar to preceding years. Incidence rates of hospitalization, intensive care admission, and death due to COVID‐19 remained in line with those for all‐cause hospitalization, intensive care admission, and mortality. Among relapsing–remitting patients on rituximab, trends for differences in risk of hospitalization due to COVID‐19 remained in the demographics‐, socioeconomic status‐, comorbidity‐, and multiple sclerosis severity‐adjusted model. Interpretation Risks of severe COVID‐19‐related outcomes were increased among multiple sclerosis patients as a whole compared to population controls, but risk increases were also seen for non‐COVID‐19 hospitalization, intensive care admission, and mortality, and did not significantly differ during the pandemic compared to pre‐pandemic years. The risk conveyed by disease‐modifying therapies was smaller than previously assumed, likely as a consequence of the possibility to better control for confounders.

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
• Subject: Age / Clinical Medicine / Clinical outcomes / Cohort analysis / Comorbidity / Coronaviruses / Country of birth / COVID-19 / Disability / Hospitalization / Immunotherapy / Intensive care / Klinisk medicin / Medical and Health Sciences / Medicin och hälsovetenskap / Monoclonal antibodies / Mortality / Multiple sclerosis / Neurologi / Neurology / Neurosciences / Neurosciences & Neurology / Neurovetenskaper / Pandemics / Patients / Population / Public health / register / Risk factors / Severe acute respiratory syndrome coronavirus 2 / Social distancing